Reporting Groups

	Description
Raltegravir 400 mg b.i.d. Plus OBT	Raltegravir 400 mg twice a day (b.i.d.) plus Optimized Background Therapy (OBT)
Placebo Plus OBT	Placebo plus Optimized Background Therapy (OBT)

Baseline Measures

	Raltegravir 400 mg b.i.d. Plus OBT	Placebo Plus OBT	Total
Number of Participants   [units: participants]	230	119	349
Age   [units: Years] Mean ( Full Range )	45.3 ( 16 to 67 )	46.5 ( 17 to 70 )	45.7 ( 16 to 70 )
Gender   [units: participants]
Female	20	12	32
Male	210	107	317
Race/Ethnicity, Customized   [units: Participants]
White	126	77	203
Black	48	21	69
Asian	2	1	3
Hispanic	47	18	65
Native American	1	0	1
Other	6	2	8
Cluster of Differentiation 4 (CD4) Cell Count   [units: cells/mm^3] Mean ( Full Range )	146 ( 1 to 757 )	163 ( 0 to 674 )	152 ( 0 to 757 )
Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA)   [units: copies/mL] Geometric Mean ( Full Range )	48366 ( 200 to 750000 )	47850 ( 200 to 750000 )	48190 ( 200 to 750000 )

1.  Primary:

Proportion of Patients Achieving HIV RNA <400 Copies/mL at Week 16   [ 16 Weeks ]

2.  Secondary:

Change From Baseline in HIV RNA at Week 16   [ Baseline and Week 16 ]

3.  Secondary:

Change From Baseline in HIV RNA at Week 48   [ Baseline and Week 48 ]

4.  Secondary:

Change From Baseline in CD4 Cell Count at Week 16   [ Baseline and Week 16 ]

5.  Secondary:

Change From Baseline in CD4 Cell Count at Week 48   [ Baseline and Week 48 ]

6.  Other Pre-specified:

Proportion of Patients Achieving HIV RNA <50 Copies/mL at Week 48   [ Week 48 ]